CRISPR Therapeutics (CRSP) Tops Q2 EPS by 26c
Tweet
Share
E-mail
Get Alerts CRSP Hot Sheet
Join SI Premium – FREE
CRISPR Therapeutics (NASDAQ: CRSP) reported Q2 EPS of ($0.94), $0.26 better than the analyst estimate of ($1.20). Revenue for the quarter came in at $10.18 million versus the consensus estimate of $7.46 million.
For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- MetaVia Inc. (MTVA) Tops Q2 EPS by 73c
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
